With negative FDA panel vote, AstraZeneca may review Lynparza’s narrow sign in prostate cancer – FiercePharma

With FDA panel’s negative vote, AstraZeneca may examine Lynparza’s narrow sign in prostate cancerFiercePharma
US FDA panel backs restricted use of AstraZeneca’s prostate cancer drugReuters.com
FDA panel rejects broad indication of olaparib in metastatic CRPCToday
FDA panel votes that proposed indication for olaparib/abiraterone should be limited to BRCA mutant mCRPCOncLive
FDA casts doubt on Merck/AstraZeneca cancer drug for prostate cancer ahead of Adcomm meetingYahoo finance
See full coverage on Google News